Home > Urology > EAU 2020 > Bladder Cancer > Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC

Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC

Presented by
Dr Neal Shore, Carolina Urologic Research Center, USA
EAU 2020
A multicentre, open-label, phase 3 study investigating nadofaragene firadenovec for high-grade, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved encouraging, durable, high-grade, recurrence-free (HGRF) survival.

Dr Neal Shore (Carolina Urologic Research Center, USA) presented the outcomes of the papillary disease (PD) cohort from the trial [1]. Nadofaragene firadenovec is a novel intravesical-administered adenovirus-mediated gene therapy (rAd-IFN) delivering the human interferon (IFN) α2b gene. When combined with the excipient Syn3, rAd-IFN/Syn3 has been shown in a phase 2 trial to be well tolerated and leads to sustained localised IFNα2b gene expression.

The phase 3 trial enrolled 157 patients (mean age 71 years), 50 of whom had PD. Intravesical administration of nadofaragene firadenovec (3×1011 viral particles/mL [75 mL]) was planned every 3 months for up to 4 doses during 12 months. All patients with an absence of high-grade disease recurrence at month 12 were offered continued treatment every 3 months. The primary endpoint was complete response (CR) at any time in the carcinoma in situ cohort (CIS ± Ta/T1, or PD [Ta/T1 alone]) unresponsive to BCG. Key secondary endpoints included the rate and durability of high-grade recurrence-free survival as well as safety in patients with PD.

The primary endpoint was met; 55 patients in the CIS cohort (n=103) achieved CR during the 12-month period (53.4%; 95% CI 43.3-63.3; see Figure). The total cohort (n=151) had 59.6% CR, whereas 72.9% of the PD subgroup (n=48) achieved CR. All CRs occurred in the first 3 months. Patients with CIS demonstrated 24.3% HGRF survival at month 12, compared with 43.8% of PD patients. In PD patients, the median duration of HGRF survival was 12.35 months (95% CI 6.67, months-not reached).

Figure: Primary endpoint analysis: complete response in patients with carcinoma in situ [1]

CIS, carcinoma in situ; HGRF, high-grade recurrence-free.
Figure kindly provided by Dr Shore.

The most common drug-related treatment-emergent adverse events were instillation site discharge (33.1%), fatigue (23.6%), bladder spasm (19.7%), micturition urgency (17.8%), and haematuria (16.6%). No patient died.

In short, nadofaragene firadenovec demonstrated clinical response in patients with high-grade BCG-unresponsive NMIBC for both CIS and PD cohorts. Responses remained durable for at least 1 year, and the safety profile and dosing schedule were acceptable. “These data represent a significant therapeutic advancement for BCG-unresponsive patients,” concluded Dr Shore.

    1. Shore N, et al. EAU20 Virtual Congress, 17-26 July 2020, Game-Changing Session 2.


© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)

Posted on